<DOC>
	<DOCNO>NCT01478828</DOCNO>
	<brief_summary>To determine dose continuous daily oral lovastatin need achieve MYC [ v-myc myelocytomatosis viral oncogene homolog ( avian ) ] down-regulation prostatectomy specimens intermediate-/high-risk localized prostate cancer patient .</brief_summary>
	<brief_title>Pre-Prostatectomy Lovastatin Prostate Cancer</brief_title>
	<detailed_description>Pharmacodynamic Phase 0 trial pre-prostatectomy lovastatin downregulate MYC localize prostate cancer . Rationale : Based available clinical preclinical data , investigator theorize high-dose lovastatin therapy decrease MYC level human prostate cancer show MYC overexpression biopsy . Experimental Methods : The investigator propose prospective , dose-finding pharmacodynamic study lovastatin intermediate/high-grade localized prostate cancer . The study involve 30 eligible patient localized prostate cancer Gleason sum 7 10 elect undergo prostatectomy Johns Hopkins . Five eligible men schedule receive oral lovastatin follow four time day schedule , start dose 12 mg/kg/day . Patients receive 2 week ( 14 day ) daily oral lovastatin prior surgery . Following initial safety monitoring period month , investigator enroll next dose level ( 20 mg/kg/day ) . Similar dose de-escalation continue three dose level ( 1 , 4 8 mg/kg/day ) 25 patient total enrolled . Following surgery , prostatectomy specimen undergo MYC immunohistochemistry ( IHC ) compare MYC IHC match biopsy sample . Pharmacodynamic efficacy ( PE ) define great 60 % inhibition MYC expression IHC great 60 % patient prostatectomy tumor specimen compare match biopsy . Expected Results : The investigator expect lovastatin enforce downregulation MYC level prostatectomy sample compare pre-lovastatin treatment core biopsy sample . The investigator also expect little toxicity patient report prior phase I II trial use similar dos lovastatin .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<criteria>1 . Adenocarcinoma prostate , without evidence spread beyond lymph node , bone , visceral organ , stage T1c high . 2 . Tumor Gleason sum 7 ( 4+3 3+4 allow ) least one core , central review prostate biopsy Johns Hopkins . However , accordance standard clinical practice , adenocarcinoma must present least two discrete biopsy section ( may vary Gleason score ) . 3 . Age â‰¥18 year age . 4 . Radical prostatectomy schedule Johns Hopkins . 5 . Willingness sign ability understand inform consent . 6 . No history treatment statinclass medication within 6 month entry trial . 7 . ECOG ( Eastern Cooperative Oncology Group ) performance status 01 . 8 . Adequate bone marrow , hepatic , renal function determine : WBC ( white blood cell ) &gt; 3,500 cells/mm3 ANC ( absolute neutrophil count ) &gt; 1,500 cells/mm3 Hemoglobin &gt; 9 g/dl Platelet count &gt; 100,000 cells/mm3 Serum creatinine &lt; 2.6 mg/dl Serum bilirubin &lt; 2 mg/dl ALT ( alanine aminotransferase ) , AST ( aspartate aminotransferase ) , Alkaline Phosphatase &lt; 2 time upper limit normal Triglycerides total cholesterol &lt; 3 time upper limit normal 1 . Patients evidence metastatic prostate cancer , include bone , visceral , brain , lymph node metastasis . 2 . Other histologic prostate cancer , include ductal , sarcomatous , lymphoma , small cell , neuroendocrine tumor . 3 . Uncontrolled medical condition could potentially increase risk toxicity complication therapy include active liver disease , unexplained persistent elevation serum transaminase , medication interfere metabolism lovastatin , gastrointestinal disease would limit ability swallow take oral medication absorb . 4 . Concurrent malignancy prostate cancer . 5 . Inability provide inform consent . 6 . Concomitant use azole antifungal , cyclosporine , clarithromycin , erythromycin , fibric acid derivative , lopinavir/ritonavir , niacin , ritonavir/saquinavir 7 . Prior chemotherapy , radiation therapy , biologic therapy , immunotherapy prostate cancer . 8 . Poor performance status ( ECOG &gt; 1 ) . 9 . Prostatectomy hospital Johns Hopkins . 10 . Prior history allergy severe reaction statin statin derivative .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>